René’s career has focused on developing biotherapeutics to impact the lives of patients. During his 9.5 years at Agensys he discovered targets for antibody therapeutics including antibody drug conjugates and later shifted to hybridoma generation and mammalian protein production. While at Xencor for 6 years, he developed expression systems for Research and for Process Development. Currently at Amgen for 5 years, René leads the Expression and Cell Engineering group in Protein Engineering which produces and optimizes large molecule therapeutics. His interests are in engineering mammalian expression hosts for improved productivity and quality and in miniaturizing and automating protein expression.